Catalyst Pharmaceuticals (CPRX) Finished Goods (2023 - 2026)

Catalyst Pharmaceuticals (CPRX) has 4 years of Finished Goods data on file, last reported at $15.3 million in Q1 2026.

• For the quarter ending Q1 2026, Finished Goods rose 88.21% year-over-year to $15.3 million; the trailing twelve-month figure through Mar 2026 stood at $15.3 million (up 88.21% YoY), and the FY2025 full-year result was $16.2 million, up 68.7% from the prior year.
• Finished Goods for Q1 2026 stood at $15.3 million, down from $16.2 million in the prior quarter.
• Across five years, Finished Goods topped out at $16.2 million in Q4 2025 and bottomed at $8.1 million in Q1 2025.
• The 4-year median for Finished Goods is $9.2 million (2024), against an average of $10.6 million.
• The widest annual swing landed in 2025, when Finished Goods fell 3.29%; it then jumped 88.21% in 2026.
• A 4-year view of Finished Goods shows it stood at $9.2 million in 2023, then increased by 4.55% to $9.6 million in 2024, then jumped by 68.7% to $16.2 million in 2025, then dropped by 5.43% to $15.3 million in 2026.
• The last three Finished Goods figures came in at $15.3 million (Q1 2026), $16.2 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.

Peer Comparison